|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Bayer_Cough_Syrup
|
|
gptkbp:activities
|
NMDA receptor antagonist
sigma-1 receptor agonist
|
|
gptkbp:affects
|
euphoria
dissociation
intoxication
|
|
gptkbp:brand
|
gptkb:Delsym
gptkb:Robitussin
|
|
gptkbp:clinical_trial
|
Phase IV
Phase II
Phase III
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
extraction from plants
|
|
gptkbp:contraindication
|
severe asthma
MAO inhibitor use
|
|
gptkbp:developed_by
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:discovered_by
|
1950s
|
|
gptkbp:dosage_form
|
10-20 mg every 4-6 hours
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dextromethorphan
|
|
gptkbp:ingredients
|
C18 H25 NO
|
|
gptkbp:interacts_with
|
gptkb:beer
MAO inhibitors
SSR Is
|
|
gptkbp:is_atype_of
|
R05 D A09
|
|
gptkbp:is_available_on
|
gptkb:product
gptkb:tablet
gptkb:mountain
suspension
|
|
gptkbp:is_used_for
|
cough suppression
|
|
gptkbp:legal_issue
|
OTC
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:fragrance
antitussive
cold medicine
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:products
|
morphine
levomethorphan
codeine
|
|
gptkbp:research
|
psychoactive effects
neurological studies
cough reflex studies
|
|
gptkbp:safety_features
|
Category C
|
|
gptkbp:side_effect
|
dizziness
nausea
allergic reactions
confusion
drowsiness
hallucinations
respiratory depression
increased heart rate
serotonin syndrome
|
|
gptkbp:threats
|
high
|
|
gptkbp:tradition
|
can develop with prolonged use
|
|
gptkbp:type_of
|
125-71-3
|